Literature DB >> 10428508

CrkL and CrkII participate in the generation of the growth inhibitory effects of interferons on primary hematopoietic progenitors.

L C Platanias1, S Uddin, E Bruno, M Korkmaz, S Ahmad, Y Alsayed, D Van Den Berg, B J Druker, A Wickrema, R Hoffman.   

Abstract

Interferons are potent regulators of normal and malignant hematopoietic cell proliferation in vitro and in vivo, but the signaling mechanisms by which they exhibit their growth inhibitory effects are unknown. We have recently shown that CrkL is engaged in Type I IFN signaling, as shown by its rapid tyrosine phosphorylation during engagement of the Type I IFN receptor. In the present study, we provide evidence that the related CrkII protein is also rapidly phosphorylated on tyrosine during treatment of U-266 and Daudi cells with IFNalpha or IFNbeta. We also show that both members of the Crk-family, CrkL and CrkII, are phosphorylated in an interferon-dependent manner in primary hematopoietic progenitors. Furthermore, inhibition of CrkL or CrkII protein expression by antisense oligonucleotides, reverses the inhibitory effects of IFNalpha or IFNgamma on the proliferation of normal bone marrow progenitor cells (colony forming units-granulocytic/monocytic [CFU-GM] and burst-forming units-erythroid [BFU-E]). Thus, both CrkL and CrkII are engaged in a signaling pathway (s) that mediates interferon-regulated inhibition of hematopoietic cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10428508     DOI: 10.1016/s0301-472x(99)00060-0

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.

Authors:  Raj Deonarain; Amit Verma; Andrew C G Porter; Dirk R Gewert; Leonidas C Platanias; Eleanor N Fish
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-03       Impact factor: 11.205

Review 2.  Interferon-zeta/limitin: novel type I interferon that displays a narrow range of biological activity.

Authors:  Kenji Oritani; Yoshiaki Tomiyama
Journal:  Int J Hematol       Date:  2004-11       Impact factor: 2.490

Review 3.  Antitumour actions of interferons: implications for cancer therapy.

Authors:  Belinda S Parker; Jai Rautela; Paul J Hertzog
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 4.  The two faces of interferon-γ in cancer.

Authors:  M Raza Zaidi; Glenn Merlino
Journal:  Clin Cancer Res       Date:  2011-06-24       Impact factor: 12.531

5.  Differential regulation of the p70 S6 kinase pathway by interferon alpha (IFNalpha) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells.

Authors:  Simrit Parmar; Jessica Smith; Antonella Sassano; Shahab Uddin; Efstratios Katsoulidis; Beata Majchrzak; Suman Kambhampati; Elizabeth A Eklund; Martin S Tallman; Eleanor N Fish; Leonidas C Platanias
Journal:  Blood       Date:  2005-03-24       Impact factor: 22.113

6.  Antiproliferative Properties of Type I and Type II Interferon.

Authors:  Joseph Bekisz; Samuel Baron; Corey Balinsky; Angel Morrow; Kathryn C Zoon
Journal:  Pharmaceuticals (Basel)       Date:  2010-03-30

7.  CXCL16-positive dendritic cells enhance invariant natural killer T cell-dependent IFNγ production and tumor control.

Authors:  Linnea Veinotte; Simon Gebremeskel; Brent Johnston
Journal:  Oncoimmunology       Date:  2016-04-22       Impact factor: 8.110

Review 8.  Role of Type I and II Interferons in Colorectal Cancer and Melanoma.

Authors:  Simone Di Franco; Alice Turdo; Matilde Todaro; Giorgio Stassi
Journal:  Front Immunol       Date:  2017-07-26       Impact factor: 7.561

9.  Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy.

Authors:  Mark J Dobrzanski
Journal:  Front Oncol       Date:  2013-03-26       Impact factor: 6.244

10.  Class A CpG oligodeoxynucleotide inhibits IFN-γ-induced signaling and apoptosis in lung cancer.

Authors:  Shuhei Teranishi; Nobuaki Kobayashi; Seigo Katakura; Chisato Kamimaki; Sousuke Kubo; Yuji Shibata; Masaki Yamamoto; Makoto Kudo; Hongmei Piao; Takeshi Kaneko
Journal:  Thorac Cancer       Date:  2020-02-17       Impact factor: 3.500

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.